My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

314.40 +5.92 (+1.92%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

June 13, 2024

Via Benzinga

Behind the Scenes of Alnylam Pharmaceuticals's Latest Options Trends ↗

June 12, 2024

Via Benzinga

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

May 17, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2024

Via Benzinga

ALNY Stock Earnings: Alnylam Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

ALNY stock results show that Alnylam Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

How Is The Market Feeling About Alnylam Pharmaceuticals? ↗

April 19, 2024

Via Benzinga

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alnylam Pharmaceuticals's Earnings Outlook ↗

February 14, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

April 09, 2024

Via Benzinga

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data ↗

April 08, 2024

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood...

Via Benzinga

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

April 02, 2024

Via Benzinga

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

3 Biotech Stocks to Buy on the Dip: March 2024 ↗

March 27, 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Via InvestorPlace

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

February 06, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗

March 18, 2024

Via Benzinga

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗

March 13, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Via InvestorPlace

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗

March 09, 2024

This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...

Via Talk Markets

Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges ↗

March 05, 2024

Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

February 28, 2024

Via Benzinga

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know ↗

February 16, 2024

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? ↗

February 15, 2024

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

Via Benzinga

Why Alnylam Pharmaceuticals Stock Is Sinking Today ↗

February 15, 2024

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Via The Motley Fool

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.